What is Maat?
Headquartered in Lyon, France, and established in 2014, Maat is a specialized oncology company dedicated to the development of microbiome-based biotherapeutics. The firm operates at the intersection of immunology and microbiology, focusing on restoring the gut microbiome to improve patient outcomes in severe disease states. As a clinical-stage entity, Maat has successfully navigated complex regulatory environments to advance its pipeline, positioning itself as a leader in the burgeoning field of microbiome restoration therapy. The company's strategic focus remains on high-impact therapeutic interventions that address significant unmet medical needs in oncology and beyond.
How much funding has Maat raised?
Maat has raised a total of $100.7M across 6 funding rounds:
Unspecified
$1.3M
Unspecified
$1.1M
Series A
$11.2M
Series B
$29.5M
Share Placement
$14M
Debt
$43.7M
Unspecified (2015): $1.3M with participation from Seventure Partners
Unspecified (2015): $1.1M led by Seventure Partners
Series A (2016): $11.2M supported by Seventure Partners
Series B (2020): $29.5M featuring Crédit Mutuel Innovation, Biocodex, Bpifrance, SymBiosis, and Seventure Partners
Share Placement (2025): $14M backed by Biocodex, RiPSIM Technologies, and Bpifrance Investissement
Debt (2025): $43.7M with participation from European Investment Bank
Key Investors in Maat
Seventure Partners
Seventure Partners is an active partner of innovative companies in the fields of digital technologies and life sciences, focusing on health, nutrition, and sustainable biotechnologies.
Biocodex
Biocodex is a multinational pharmaceutical company with a deep specialization in microbiota and neurology, leveraging over 60 years of experience in the healthcare sector.
European Investment Bank
The European Investment Bank is the nonprofit long-term lending institution of the European Union, providing critical financial support for large-scale innovation and infrastructure projects.
What's next for Maat?
With the recent influx of capital, Maat is well-positioned to accelerate its clinical trial milestones and expand its research infrastructure. The company's trajectory, supported by a diverse syndicate of institutional investors and long-term lending partners, suggests a focus on scaling its manufacturing capabilities and broadening its therapeutic reach. As Maat moves deeper into its clinical roadmap, the focus will likely shift toward commercialization readiness and the potential for strategic partnerships to enhance its global distribution footprint. The firm remains a key entity to watch as it continues to validate its biotherapeutic platform through rigorous clinical data and sustained financial support.
See full Maat company page
